- Home
- HXL vs GH Comparison
HXL vs GH Comparison
Compare HXL & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HXL
- GH
- Stock Information
- Founded
- HXL 1946
- GH 2011
- Country
- HXL United States
- GH United States
- Employees
- HXL N/A
- GH N/A
- Industry
- HXL Major Chemicals
- GH Medical Specialities
- Sector
- HXL Industrials
- GH Health Care
- Exchange
- HXL Nasdaq
- GH Nasdaq
- Market Cap
- HXL 4.4B
- GH 4.9B
- IPO Year
- HXL N/A
- GH 2018
- Fundamental
- Price
- HXL $54.39
- GH $49.14
- Analyst Decision
- HXL Hold
- GH Strong Buy
- Analyst Count
- HXL 10
- GH 20
- Target Price
- HXL $61.20
- GH $54.35
- AVG Volume (30 Days)
- HXL 1.2M
- GH 2.2M
- Earning Date
- HXL 07-17-2025
- GH 08-06-2025
- Dividend Yield
- HXL 1.25%
- GH N/A
- EPS Growth
- HXL 29.12
- GH N/A
- EPS
- HXL 1.51
- GH N/A
- Revenue
- HXL $1,887,200,000.00
- GH $773,996,000.00
- Revenue This Year
- HXL $1.37
- GH $23.14
- Revenue Next Year
- HXL $11.15
- GH $21.42
- P/E Ratio
- HXL $36.00
- GH N/A
- Revenue Growth
- HXL 4.63
- GH 28.20
- 52 Week Low
- HXL $45.28
- GH $20.14
- 52 Week High
- HXL $71.05
- GH $52.92
- Technical
- Relative Strength Index (RSI)
- HXL 50.37
- GH 62.17
- Support Level
- HXL $54.04
- GH $48.00
- Resistance Level
- HXL $55.59
- GH $51.71
- Average True Range (ATR)
- HXL 1.41
- GH 2.67
- MACD
- HXL -0.20
- GH 0.39
- Stochastic Oscillator
- HXL 41.32
- GH 78.60
About HXL Hexcel Corporation
Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use in the commercial aerospace, defense, and high-performance automotive markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engines, and other components and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (38% of 2022 sales) and Boeing (25% of prepandemic sales) and their respective subcontractors.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.